Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States

"The name Tavalisse (pronounced - ta vah lees') was developed based on the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. Created with the help of experts in this field, the proprietary name development included input from prescribers, pharmacists, linguists and employees to create a unique and approachable name.

Earlier this month, the company announced that it submitted a New Drug Application (NDA) to the FDA for Tavalisse in patients with chronic and persistent immune thrombocytopenia (ITP). The FDA previously granted Orphan Drug designation to Tavalisse for the treatment of patients with ITP."

- From Rigel Pharmaceuticals, Inc. press release.

Read More

back to top
Charity Navigator
GuideStar Seal
NORD Member Badge
THSNA logo
THSNA Summit 2024
April 3-6th